1. Home
  2. EVC vs GALT Comparison

EVC vs GALT Comparison

Compare EVC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$2.73

Market Cap

233.8M

Sector

Industrials

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$5.74

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVC
GALT
Founded
1996
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
232.3M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
EVC
GALT
Price
$2.73
$5.74
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.00
AVG Volume (30 Days)
335.2K
390.3K
Earning Date
11-04-2025
11-14-2025
Dividend Yield
7.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$420,178,000.00
N/A
Revenue This Year
$64.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.96
N/A
52 Week Low
$1.58
$0.73
52 Week High
$3.15
$6.66

Technical Indicators

Market Signals
Indicator
EVC
GALT
Relative Strength Index (RSI) 56.75 53.34
Support Level $2.75 $5.31
Resistance Level $2.85 $5.88
Average True Range (ATR) 0.11 0.50
MACD -0.02 -0.01
Stochastic Oscillator 60.94 38.46

Price Performance

Historical Comparison
EVC
GALT

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: